Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus

Abstract

Objective

To examine longitudinal associations of active lupus nephritis with organ damage accrual in patients with systemic lupus erythematosus (SLE).

Methods

This study was performed using data from a large multinational prospective cohort. Active lupus nephritis at any visit was defined by the presence of urinary casts, proteinuria, haematuria or pyuria, as indicated by the cut-offs in the SLE Disease Activity Index (SLEDAI)-2K, collected at each visit. Organ damage accrual was defined as a change of SLICC-ACR Damage Index (SDI) score >0 units between baseline and final annual visits. Renal damage accrual was defined if there was new damage recorded in renal SDI domains (estimated glomerular filtration rate <50%/proteinuria >3.5 g per 24 h/end-stage kidney disease). Time-dependent hazard regression analyses were used to examine the associations between active lupus nephritis and damage accrual.

Results

Patients (N = 1735) were studied during 12,717 visits for a median (inter-quartile range) follow-up period of 795 (532, 1087) days. Forty per cent of patients had evidence of active lupus nephritis at least once during the study period, and active lupus nephritis was observed in 3030 (24%) visits. Forty-eight per cent of patients had organ damage at baseline and 14% accrued organ damage. Patients with active lupus nephritis were 52% more likely to accrue any organ damage compared with those without active lupus nephritis (adjusted hazard ratio = 1.52 (95% confidence interval (CI): 1.16, 1.97), p < 0.02). Active lupus nephritis was strongly associated with damage accrual in renal but not in non-renal organ domains (hazard ratios = 13.0 (95% CI: 6.58, 25.5) p < 0.001 and 0.96 (95% CI: 0.69, 1.32) p = 0.8, respectively). There was no effect of ethnicity on renal damage accrual, but Asian ethnicity was significantly associated with reduced non-renal damage accrual.

Conclusion

Active lupus nephritis measured using the SLEDAI-2K domain cut-offs is associated with renal, but not non-renal, damage accrual in SLE.

Keywords

Lupus nephritis organ damage accrual

Get full access to this article

View all access options for this article.

References

Almaani

Meara

Rovin

. Update on lupus nephritis. Clin J Am Soc Nephrol 2017; 12: 825–835.

Hanly

O’Keeffe

, et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford) 2016; 55: 252–262.

Mak

Isenberg

Lau

. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol 2013; 9: 301–310.

Jorge

Zhang

Rai

Choi

. Unchanging premature mortality trends in systemic lupus erythematosus: A general population-based study (1999-2014). Rheumatology (Oxford) 2018; 57: 337–344.

Rahman

Gladman

Urowitz

Hallett

Tam

. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93–96.

Bruce

O’Keeffe

Farewell

, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015; 74: 1706–1713.

Apostolopoulos

Kandane-Rathnayake

Raghunath

, et al. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med 2016; 3: e000157–e000157.

Jakes

Bae

Louthrenoo

Mok

Navarra

Kwon

. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012; 64: 159–168.

Yap

Chan

. Lupus Nephritis in Asia: Clinical features and management. Kidney Dis (Basel) 2015; 1: 100–109.

10.

Kandane-Rathnayake

Golder

Louthrenoo

, et al. Development of the Asia Pacific Lupus Collaboration cohort. Int J Rheum Dis 2019; 22: 425–433.

11.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

12.

Petri

Orbai

Alarcon

, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

13.

Stoll

Seifert

Isenberg

. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254.

14.

Gladman

Ibanez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

15.

Isenberg

Allen

Farewell

, et al. An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011; 70: 54–59.

16.

Petri

Buyon

Kim

. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685–691.

17.

Chambers

Allen

Rahman

Isenberg

. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009; 48: 673–675.

18.

Amorim

Cai

. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol 2015; 44: 324–333.

19.

Franklyn

Lau

Navarra

, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.

20.

Tamirou

D’Cruz

Sangle

, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 2016; 75: 526–531.

21.

Tamirou

Lauwerys

Dall’Era

, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2015; 2: e000123–e000123.

22.

Bastian

Roseman

McGwin

Jr , et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152–160.

23.

Jacobsen

Petersen

Ullman

, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998; 17: 468–477.

24.

Dall’Era

Cisternas

Smilek

, et al. Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305–1313.

25.

Koo

Kim

Chin

. Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis. Lupus 2016; 25: 3–11.

26.

Korbet

Lewis

. Collaborative Study Group. Severe lupus nephritis: the predictive value of a ≥50% reduction in proteinuria at 6 months. Nephrol Dial Transplant 2013; 28: 2313–2318.

27.

Cavanaugh

Perazella

. Urine sediment examination in the diagnosis and management of kidney disease: Core curriculum 2019. Am J Kidney Dis 2019; 73: 258–272.

28.

Peschken

Katz

Silverman

, et al. The 1000 Canadian faces of lupus: Determinants of disease outcome in a large multiethnic cohort. J Rheumatol 2009; 36: 1200–1208.

29.

Osio-Salido

Manapat-Reyes

. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010; 19: 1365–1373.

30.

Johnson

Urowitz

Ibanez

Gladman

. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J Rheumatol 2006; 33: 1990–1995.

31.

Anders

Rovin

. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 2016; 90: 493–501.

32.

Condon

Ashby

Pepper

, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280–1286.

33.

Hahn

McMahon

Wilkinson

, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.

34.

Bertsias

Tektonidou

Amoura

, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771–1782.

35.

KDIGO. KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 221–232.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB